WO2001091762A1 - Compositions d'apport complementaire de zinc destinees a une administration par voie orale - Google Patents
Compositions d'apport complementaire de zinc destinees a une administration par voie orale Download PDFInfo
- Publication number
- WO2001091762A1 WO2001091762A1 PCT/JP2001/004478 JP0104478W WO0191762A1 WO 2001091762 A1 WO2001091762 A1 WO 2001091762A1 JP 0104478 W JP0104478 W JP 0104478W WO 0191762 A1 WO0191762 A1 WO 0191762A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- zinc
- dipeptide
- complex
- composition
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 57
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 57
- 239000011701 zinc Substances 0.000 claims abstract description 57
- 150000003751 zinc Chemical class 0.000 claims abstract description 17
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 14
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Chemical class CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims abstract description 10
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical class CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims abstract description 10
- 239000002253 acid Chemical class 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 17
- 239000004246 zinc acetate Substances 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 206010048259 Zinc deficiency Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000011785 micronutrient Substances 0.000 claims description 3
- 235000013369 micronutrients Nutrition 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical group [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- QNDQILQPPKQROV-UHFFFAOYSA-N dizinc Chemical compound [Zn]=[Zn] QNDQILQPPKQROV-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000001502 supplementing effect Effects 0.000 claims description 2
- 229960000314 zinc acetate Drugs 0.000 claims description 2
- 239000011576 zinc lactate Substances 0.000 claims description 2
- 229940050168 zinc lactate Drugs 0.000 claims description 2
- 235000000193 zinc lactate Nutrition 0.000 claims description 2
- 229940091251 zinc supplement Drugs 0.000 claims description 2
- 108010087806 Carnosine Proteins 0.000 abstract description 9
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 abstract description 9
- CCLQKVKJOGVQLU-QMMMGPOBSA-N L-homocarnosine Chemical class NCCCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 CCLQKVKJOGVQLU-QMMMGPOBSA-N 0.000 abstract description 8
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical class [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 abstract description 7
- SLRNWACWRVGMKD-QMMMGPOBSA-N Balenine Chemical class CN1C=NC(C[C@H](N=C(O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-QMMMGPOBSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000013522 chelant Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- -1 L-carnosine methyl ester Chemical class 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- LIPRKYKMVQPYPG-UHFFFAOYSA-N 3-Hydroxy-2H-pyran-2-one Chemical class OC1=CC=COC1=O LIPRKYKMVQPYPG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-IGMARMGPSA-N Calcium-40 Chemical compound [40Ca] OYPRJOBELJOOCE-IGMARMGPSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021413 well-balanced diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention enhances the absorption of zinc from the gastrointestinal tract to be administered as a medicine to treat zinc deficiency or as a supplement (health food) to supplement zinc as a micronutrient Or the composition to be ingested.
- Zinc is a trace element necessary for living organisms and plays an important role in sustaining life. Comprehensive information on the form, function, and symptoms of zinc deficiency in the body, as well as the mechanism of absorption and intestinal absorption from the intestinal tract can be found in, for example, C.T.Walsh et al. Enviro nmental Health Perspect 10 2 (1994): Supplement 2, 5—46. It is known that there are more than 300 kinds of enzymes containing zinc in living organisms, and many of them have zinc at the active center. Representative of these are alkaline phosphatase, carbonic anhydride, carboxypeptidase, alcohol dehydrogenase and the like. Zinc is also present in proteins that activate replication of DNA and RNA.
- zinc expresses its protein function by forming a special domain structure called zinc finger.
- the amount of zinc present in human organisms is about 3 g, and in small but deficient levels, systemic body function is impaired. In other words, abnormal taste and smell, suppression of growth, decreased reproductive function, decreased immunity, and neuropsychiatric disorders It is caused by throat.
- Zinc is absorbed from the intestinal tract. At this time, it forms a chelate with a low-molecular-weight carrier substance, passes through the brush-border membrane of the small intestine, is transported from the intestinal lumen into the intestinal cells, and becomes zinc-zinc. It is temporarily stored in the form of, and released into the blood as needed, and transported to tissues in the body. It is not yet clear what molecules become zinc carriers upon absorption. It is estimated that amino acids, di- and tripeptides can be such carriers because a high protein diet enhances zinc absorption. In addition, there is said that proteins that contain a large amount of cystine (CRIP) and 2-picolinic acid contained in liquid and bile are also carriers for zinc transport.
- cystine CRIP
- 2-picolinic acid contained in liquid and bile are also carriers for zinc transport.
- a number of carrier substances have been described that form chelate with zinc and promote absorption from the gastrointestinal tract. Examples thereof include L-glutamic acid (JP-A-57-82318), natural amino acids, di-, tri-, or tetrapeptides of natural amino acids. 3-5 0 2 7 4 9), sugar phosphates (Japanese Patent Application Laid-Open No. 2-249468), and hydroxypyrones (Japanese Patent Application Laid-Open No. 60-115564). Others claim that picolinic acid and prostaglandin are also effective, but have not been adequately proven.
- the zinc carrier material must be highly effective and highly reliable in terms of safety.
- the proposed carrier materials have not been satisfactory in both efficacy and safety, and further improvements are desired.
- the present invention provides a new finding that the above-mentioned demand is satisfied by selecting L-l-Lunosine, L-homocarnosine, L-anserine, L-valenin, an acid salt or an ester thereof as a carrier material for zinc. It is based.
- the present invention provides a physiologically acceptable zinc salt selected from the group consisting of L-carnosine, L-homocarnosine, L-anserine, L-nocrenin, and acid salts and esters thereof.
- a physiologically acceptable zinc salt selected from the group consisting of L-carnosine, L-homocarnosine, L-anserine, L-nocrenin, and acid salts and esters thereof.
- a mixture in which the molar ratio of the peptide to the zinc salt with respect to the zinc salt is 0.5 or more, or zinc supplementation by oral administration comprising the zinc complex of the peptide.
- a supply composition is provided.
- composition may be in the form of tablets, capsules, powders, granules or solid dosage forms for oral administration, as a medicament for the treatment of zinc deficiency, or a dietary supplement for supplementing zinc as a micronutrient. It can be administered as
- L-carnosine also known as N-—alanyl L-histidine
- L-ancenline also known as N- _ aranyl- 3 -methyl-L-histidine
- L-n-renin also known as N-mono-alanyl- 1 -methyl histidine
- L-Homocarnosine is a dipeptide of L-histidine and ⁇ -aminobutyric acid (GABA).
- amino acids and peptides have been proposed as carrier substances for efficiently absorbing zinc from the intestinal tract. These are -amino acids and peptides composed of them. It is not known to use peptides containing carrier amino acids or as primary amino acids.
- L-carnosine, L-homocarnosine, L-anserine and L-valenin can be obtained by extraction from vertebrate muscle tissue.
- L-carnosine, L-homocarnosine, L-anserine and L-valenin are examples of their acid salts.
- it may be administered in the form of a hydrochloride or an ester such as a lower alkyl ester such as methyl and ethyl.
- the zinc salt administered with these peptides must be capable of ionizing zinc ions in the gastrointestinal tract and forming chelates with the dipeptides.
- these salts must generally be readily soluble in water or digestive juices and must be physiologically tolerated for long periods of time.
- examples of preferred zinc salts are zinc sulfate, zinc acetate, zinc lactate, and the like.
- Extracts rich in zinc salts such as meats such as porcelain, pigs, hidges, and nits, the offal of these animals (liver, eyes, prostate, etc.), seaweeds (konbu, wakame, hijiki, glue, etc.) Extracts such as oysters and oysters may be used as a source of zinc salt.
- the ratio of dipeptides (L-Lunosine, L-Homocarnosine, L-Anserine, L-Valenine, acid salts or esters thereof) to zinc salt is 0.5 or more in molar ratio to zinc atom. Although it must, zinc bioavailability increases with increasing molar ratio to zinc atoms. However, from an economic point of view, a molar ratio of 1 to 30, especially 1 to 10, may be appropriate.
- the dipeptide forms a complex with zinc. See Tokuhei 3—5 3 8 7. This complex can be used alone instead of the mixture. Also, a mixture of this complex and the above-mentioned peptide in the above-mentioned molar ratio can be used.
- composition of the present invention can be processed into a solid preparation suitable for oral administration such as tablets, capsules, powders and granules by a conventional method.
- An enteric solution is preferred to avoid the effects of stomach acid.
- the daily intake of zinc is 10-15 mg for children, 15 mg for adult boys, ideally 20-; L 0 mg, 15 mg for adult girls, pregnant women Is 20 mg for breastfeeding and 25 mg for nursing women. Based on these, the dosage of the above formulation can be determined.
- the safety of zinc is well established and there is little concern about overdose toxicity o
- the zinc absorption was determined from the integrated value (AUC) of the blood zinc concentration / time curve up to 7 hours, and the bioavailability (B A) was calculated from the ratio to the AUC when zinc acetate 1 mg / kg was intravenously administered. Table 1 shows the results.
- the molar ratio of L-One-Lunosine to zinc acetate was 1: 1 and the amount of zinc was varied from 3 mg / kg to 10 O mgZkg.
- the AUC and bioavailability were determined as in Experiment 1, and compared with the case of zinc acetate alone. The results are shown in the graph of FIG.
- L-Lunosine zinc complex (1: 1) 100 mg lactose 50.0 mg corn starch 23 35 mg carboxymethyl cellulose calcium 40 mg methyl cellulose 20 mg magnesium stearate 0 5 mg
- Each component is taken according to the following formulation ratio, granulated by a conventional method, and filled into No. 2 capsule to obtain a hard capsule.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU58857/01A AU5885701A (en) | 2000-05-31 | 2001-05-28 | Zinc-supplementary compositions for oral administration |
CA002380367A CA2380367A1 (en) | 2000-05-31 | 2001-05-28 | Compositions for providing zinc through oral administration |
EP01932310A EP1285660A4 (en) | 2000-05-31 | 2001-05-28 | ZINC SUPPLEMENTARY COMPOSITIONS FOR ORAL ADMINISTRATION |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000161444 | 2000-05-31 | ||
JP2000-161444 | 2000-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001091762A1 true WO2001091762A1 (fr) | 2001-12-06 |
Family
ID=18665468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/004478 WO2001091762A1 (fr) | 2000-05-31 | 2001-05-28 | Compositions d'apport complementaire de zinc destinees a une administration par voie orale |
Country Status (5)
Country | Link |
---|---|
US (1) | US20020150629A1 (ja) |
EP (1) | EP1285660A4 (ja) |
AU (1) | AU5885701A (ja) |
CA (1) | CA2380367A1 (ja) |
WO (1) | WO2001091762A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007086354A1 (ja) | 2006-01-24 | 2007-08-02 | Nippon Zoki Pharmaceutical Co., Ltd. | 新規ヒスチジン誘導体 |
JP2009001497A (ja) * | 2007-06-19 | 2009-01-08 | Univ Nihon | 抗菌剤 |
WO2009014097A1 (ja) | 2007-07-23 | 2009-01-29 | Nippon Zoki Pharmaceutical Co., Ltd. | 新規ヒスチジン誘導体 |
JP2011514316A (ja) * | 2008-02-08 | 2011-05-06 | ピュラック バイオケム ビー.ブイ. | 金属ラクテート粉及び製造方法 |
JP2011236186A (ja) * | 2010-05-13 | 2011-11-24 | Toshihiko Shinomiya | 亜鉛錯体とプロスタグランジン等からなる外用剤 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080210A1 (en) * | 2003-03-14 | 2004-09-23 | Boehringer Ingelheim Danmark A/S | Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea |
TWI766106B (zh) | 2017-09-29 | 2022-06-01 | 荷蘭商耐克創新有限合夥公司 | 具有結構性色彩的物件 |
EP3969947A1 (en) | 2019-06-26 | 2022-03-23 | Nike Innovate C.V. | Structurally-colored articles and methods for making and using structurally-colored articles |
WO2021021562A1 (en) | 2019-07-26 | 2021-02-04 | Nike, Inc. | Structurally-colored articles and methods for making and using structurally-colored articles |
US11986042B2 (en) | 2019-10-21 | 2024-05-21 | Nike, Inc. | Structurally-colored articles and methods for making and using structurally-colored articles |
EP4107007B1 (en) | 2020-05-29 | 2023-08-30 | Nike Innovate C.V. | Structurally-colored articles and methods for making and using structurally-colored articles |
US11129444B1 (en) | 2020-08-07 | 2021-09-28 | Nike, Inc. | Footwear article having repurposed material with concealing layer |
US11241062B1 (en) | 2020-08-07 | 2022-02-08 | Nike, Inc. | Footwear article having repurposed material with structural-color concealing layer |
US11889894B2 (en) | 2020-08-07 | 2024-02-06 | Nike, Inc. | Footwear article having concealing layer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1088425A (en) * | 1976-12-17 | 1980-10-28 | Harvey H. Ashmead | Bio-available essential metals |
JPH0797323A (ja) * | 1993-05-07 | 1995-04-11 | Suntory Ltd | 鉄吸収促進剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2811331B2 (ja) * | 1989-10-02 | 1998-10-15 | ゼリア新薬工業株式会社 | 骨形成促進剤 |
JP3877807B2 (ja) * | 1996-07-03 | 2007-02-07 | ゼリア新薬工業株式会社 | 口内炎治療・予防剤 |
-
2001
- 2001-05-28 EP EP01932310A patent/EP1285660A4/en not_active Withdrawn
- 2001-05-28 US US10/048,411 patent/US20020150629A1/en not_active Abandoned
- 2001-05-28 WO PCT/JP2001/004478 patent/WO2001091762A1/ja not_active Application Discontinuation
- 2001-05-28 AU AU58857/01A patent/AU5885701A/en not_active Abandoned
- 2001-05-28 CA CA002380367A patent/CA2380367A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1088425A (en) * | 1976-12-17 | 1980-10-28 | Harvey H. Ashmead | Bio-available essential metals |
JPH0797323A (ja) * | 1993-05-07 | 1995-04-11 | Suntory Ltd | 鉄吸収促進剤 |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 87204404 * |
CHO C.H. ET AL.: "Zinc deficiency: its role in gastric secretion and stress-induced gastric ulceration in rats", PHARMACOL. BIOCHEM. BEHAV., vol. 26, no. 2, February 1987 (1987-02-01), pages 293 - 297, XP002941792 * |
TAKEFUMI MATSUKURA ET AL.: "Characterization of crystalline L-carnosine Zn(II) complex (Z-103), a novel anti-gastric ulcer agent: Tautomeric change of imidazole moiety upon complexation", CHEM. PHARM. BULL., vol. 38, no. 11, 1990, pages 3140 - 3146, XP002941791 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007086354A1 (ja) | 2006-01-24 | 2007-08-02 | Nippon Zoki Pharmaceutical Co., Ltd. | 新規ヒスチジン誘導体 |
US8236844B2 (en) | 2006-01-24 | 2012-08-07 | Nippon Zoki Pharmaceutical Co., Ltd. | Histidine derivatives |
JP2009001497A (ja) * | 2007-06-19 | 2009-01-08 | Univ Nihon | 抗菌剤 |
WO2009014097A1 (ja) | 2007-07-23 | 2009-01-29 | Nippon Zoki Pharmaceutical Co., Ltd. | 新規ヒスチジン誘導体 |
US8324261B2 (en) | 2007-07-23 | 2012-12-04 | Nippon Zoki Pharmaceutical Co., Ltd. | Histidine derivatives |
JP2011514316A (ja) * | 2008-02-08 | 2011-05-06 | ピュラック バイオケム ビー.ブイ. | 金属ラクテート粉及び製造方法 |
JP2015120699A (ja) * | 2008-02-08 | 2015-07-02 | ピュラック バイオケム ビー. ブイ. | 金属ラクテート粉及び製造方法 |
JP2011236186A (ja) * | 2010-05-13 | 2011-11-24 | Toshihiko Shinomiya | 亜鉛錯体とプロスタグランジン等からなる外用剤 |
Also Published As
Publication number | Publication date |
---|---|
US20020150629A1 (en) | 2002-10-17 |
CA2380367A1 (en) | 2001-12-06 |
EP1285660A1 (en) | 2003-02-26 |
EP1285660A4 (en) | 2003-07-09 |
AU5885701A (en) | 2001-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001091762A1 (fr) | Compositions d'apport complementaire de zinc destinees a une administration par voie orale | |
WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
JP6987757B2 (ja) | 新規トリペプチド | |
JPH10108647A (ja) | 胃切除術後患者用ミネラル補給材 | |
WO2009035169A1 (ja) | 血圧上昇抑制作用を有するぺプチド | |
CN105935364B (zh) | 用于预防或治疗非酒精性肝病的包含人参皂苷f2的组合物 | |
JPH01294631A (ja) | 糖尿性疾患治療予防剤及び飲食、し好物 | |
JP5100033B2 (ja) | 消化管及び腎臓の萎縮抑制剤 | |
JP2007161642A (ja) | アルコール性肝障害抑制剤 | |
EP2773363A1 (en) | Nutritional supplement for weight management | |
JP2008088162A (ja) | 睡眠補助剤および睡眠補助食品 | |
JPH0797323A (ja) | 鉄吸収促進剤 | |
JPH06145061A (ja) | 抗皮膚癌剤又は食品 | |
JPH0667833B2 (ja) | 経腸栄養剤 | |
JP5317456B2 (ja) | 内因性オピオイドペプチドの血中分泌促進用組成物 | |
US6881750B2 (en) | Potassium taurate bicarbonate and ascorbate | |
JP2003192584A (ja) | 高血圧症予防・改善用組成物 | |
JP5294194B2 (ja) | 脳血管性認知症の治療薬 | |
JP2007320947A (ja) | 血糖値上昇抑制剤 | |
JP2005239686A (ja) | 脂肪燃焼促進組成物及び該組成物を含有する食品又は医薬品 | |
JP4111429B2 (ja) | 骨粗鬆症予防剤又は治療剤 | |
JP2013014590A (ja) | 消化管及び腎臓の萎縮抑制剤 | |
JP3523248B2 (ja) | コレステロール低減化ペプチド | |
JPH06247876A (ja) | アルコール性肝障害軽減剤 | |
JP2005224169A (ja) | ダイエット加工食品原料及びその原料を用いたダイエット加工食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 58857/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2380367 Country of ref document: CA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10048411 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001932310 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001932310 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001932310 Country of ref document: EP |